SEATTLE, Nov. 1, 2016 /PRNewswire/ -- Sound Pharmaceuticals, a pioneer in the development of novel drug treatments for inner ear disease, announces the hiring of two senior executives. Paul Hoskins, Senior Director of Clinical Operations and G. Michael Wall, Senior Director of Pharmaceutical Development joined the company this past month.
Paul Hoskins has over a 20 year history in biotech and pharma and was most recently an Executive Director of Clinical Research at Merck. Mr. Hoskins has a significant background in both discovery science and early and late stage clinical trials in CNS. He has contributed to five NDAs, and has provided operational expertise to over 30 first-in-man trials in the US, EU, Asia and Latin America. In addition, Mr. Hoskins served in the US Air Force as a combat medic for four years after college. Mr. Wall has over a 25 year history in the biotechnology and pharmaceutical industry, and was a Senior Director of Alcon, now Novartis, for two decades. While at Alcon, Mr. Wall led the development and approval of Ciprodex (antibiotic/steroid otic drops for ear infections) and Patanase (antihistamine nasal spray for allergic rhinitis). “We are pleased to have two experienced biotech executives join our team and advance our clinical trials in this important area of neurotology” said Jonathan Kil, MD, Co-Founder and CEO. Meniere’s disease has no FDA approved products, and is often managed with diet, diuretics and steroids, which are not disease modifying.
About Sound Pharmaceuticals Sound Pharmaceuticals, Inc. (SPI) is a pioneer in neurotologic drug development aimed at treating sensorineural diseases of the inner ear. SPI is developing the first therapeutics that will enable doctors and patients to prevent and treat various forms of hearing loss and tinnitus including chemotherapy and antibiotic induced ototoxicity and Meniere’s disease. Sensorineural hearing loss is the third largest chronic disease and affects 50 million Americans. Current treatments for most hearing loss involve hearing aids and aural rehabilitative therapy, which do not modify the disease or its progression. Meniere’s disease involves vertigo, hearing loss and tinnitus and affects 600,000 in the US, and approximately 5 million worldwide.
Contact: www.soundpharma.comor Paul Rickeyir@soundpharma.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sound-pharmaceuticals-announces-two-new-executive-hires-to-accelerate-its-menieres-drug-development-program-300354616.html
SOURCE Sound Pharmaceuticals
